Generation of Small Molecule Asthma Disease Modifying Agents from a TB Derived Peptide Lead

PeptInnoate是一家药物发现和开发公司，总部设在葛兰素史克网站上的Stevenage Bioscience Catalyst。该公司的核心研究是基于从结核分枝杆菌蛋白质中提取的分子，作为治疗慢性炎症性疾病的创新免疫调节剂。先导分子PIN201104是一种极其安全的低分子多肽，由表型药物发现与英国多个领先的学术团体合作确定。PIN201104正在作为治疗哮喘和其他慢性炎症性疾病的一流疾病改良剂进入临床。通过这笔赠款，PeptInnoate将利用它为PIN201104确定的疾病修改方法来产生小分子类似物。在该项目之后对这些类似物进行进一步的改造，将允许产生用于治疗轻、中度哮喘患者的口服活性疾病改良剂。目前还没有用于治疗哮喘的疾病改良剂。PeptInnoate正在率先发现有可能改变慢性炎症性哮喘潜在疾病并导致潜在治疗方法的药物。

Peptinnovate is a drug discovery and development company based in the Stevenage Bioscience Catalyst on the GSK site. The company's core research is based on molecules derived from Mycobacterium tuberculosis proteins as innovative immunomodulatory agents for the treatment of chronic inflammatory diseases. The lead molecule PIN201104 is an extremely safe, low molecular weight peptide identified by phenotypic drug discovery in collaboration with a number of leading UK academic groups. PIN201104 is being progressed into the clinic as a first in class disease modifying agent for the treatment of asthma and other chronic inflammatory conditions. Peptinnovate through this grant will exploit the disease modifying approach it has identified for PIN201104 to generate small molecule analogues. Further modification of these analogues subsequent to this project will allow the generation of orally active disease modifying agents for the treatment of mild to moderate asthmatics. There are currently no disease modifying agents available for the treatment of asthma. Peptinnovate is pioneering the discovery of agents with the potential to change the underlying disease of chronic inflammatory asthma and lead to potential curative therapies.